Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit - Johnson & Johnson (NYSE:JNJ) — alphai